These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

462 related articles for article (PubMed ID: 23177180)

  • 1. Efinaconazole 10% solution in the treatment of toenail onychomycosis: Two phase III multicenter, randomized, double-blind studies.
    Elewski BE; Rich P; Pollak R; Pariser DM; Watanabe S; Senda H; Ieda C; Smith K; Pillai R; Ramakrishna T; Olin JT
    J Am Acad Dermatol; 2013 Apr; 68(4):600-608. PubMed ID: 23177180
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efinaconazole solution in the treatment of toenail onychomycosis: a phase 2, multicenter, randomized, double-blind study.
    Tschen EH; Bucko AD; Oizumi N; Kawabata H; Olin JT; Pillai R
    J Drugs Dermatol; 2013 Feb; 12(2):186-92. PubMed ID: 23377392
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efinaconazole topical, 10% for the treatment of toenail onychomycosis in patients with diabetes.
    Vlahovic TC; Joseph WS
    J Drugs Dermatol; 2014 Oct; 13(10):1186-90. PubMed ID: 25607552
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic Factors for Complete Cure Following Treatment of Mild and Moderate Toenail Onychomycosis With Efinaconazole Topical Solution 10.
    Jellinek NJ; Korotzer A
    J Drugs Dermatol; 2015 Aug; 14(8):871-5. PubMed ID: 26267732
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efinaconazole topical solution, 10%: the benefits of treating onychomycosis early.
    Rich P
    J Drugs Dermatol; 2015 Jan; 14(1):58-62. PubMed ID: 25607909
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Is Severity of Disease a Prognostic Factor for Cure Following Treatment of Onychomycosis?
    Elewski BE; Cantrell W; Lin T
    J Drugs Dermatol; 2018 Feb; 17(2):175-178. PubMed ID: 29462225
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efinaconazole Topical Solution, 10% Efficacy in Patients with Onychomycosis and Coexisting Tinea Pedis.
    Markinson B; Caldwell B
    J Am Podiatr Med Assoc; 2015 Sep; 105(5):407-11. PubMed ID: 26429609
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-Term Follow-up of Onychomycosis Patients Treated With Efinaconazole.
    Pollak RA; Ilie C
    J Drugs Dermatol; 2017 Dec; 16(12):1269-1273. PubMed ID: 29240863
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efinaconazole 10% topical solution for the topical treatment of onychomycosis of the toenail.
    Lipner SR; Scher RK
    Expert Rev Clin Pharmacol; 2015; 8(6):719-31. PubMed ID: 26325488
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety, Pharmacokinetics, and Efficacy of Efinaconazole 10% Topical Solution for Onychomycosis Treatment in Pediatric Patients.
    Eichenfield LF; Elewski B; Sugarman JL; Rosen T; Vlahovic TC; Gupta AK; Stein Gold L; Pillai R; Guenin E
    J Drugs Dermatol; 2020 Sep; 19(9):867-872. PubMed ID: 33026753
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ciclopirox nail lacquer topical solution 8% in the treatment of toenail onychomycosis.
    Gupta AK; Fleckman P; Baran R
    J Am Acad Dermatol; 2000 Oct; 43(4 Suppl):S70-80. PubMed ID: 11051136
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efinaconazole topical solution, 10%: the development of a new topical treatment for toenail onychomycosis.
    Pollak RA
    J Am Podiatr Med Assoc; 2014 Nov; 104(6):568-73. PubMed ID: 25514267
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of tavaborole topical solution, 5%, a novel boron-based antifungal agent, for the treatment of toenail onychomycosis: Results from 2 randomized phase-III studies.
    Elewski BE; Aly R; Baldwin SL; González Soto RF; Rich P; Weisfeld M; Wiltz H; Zane LT; Pollak R
    J Am Acad Dermatol; 2015 Jul; 73(1):62-9. PubMed ID: 25956661
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of topical terbinafine 10% solution (MOB-015) in the treatment of mild to moderate distal subungual onychomycosis: A randomized, multicenter, double-blind, vehicle-controlled phase 3 study.
    Gupta AK; Surprenant MS; Kempers SE; Pariser DM; Rensfeldt K; Tavakkol A
    J Am Acad Dermatol; 2021 Jul; 85(1):95-104. PubMed ID: 32585278
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The efficacy and safety of efinaconazole 10% solution for treatment of mild to moderate onychomycosis: a pooled analysis of two phase 3 randomized trials.
    Gupta AK; Elewski BE; Sugarman JL; Ieda C; Kawabata H; Kang R; Pillai R; Olin JT; Watanabe S
    J Drugs Dermatol; 2014 Jul; 13(7):815-20. PubMed ID: 25007364
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A phase II, randomized, double-blind, placebo-controlled, parallel group, dose-ranging study to investigate the efficacy and safety of 4 dose regimens of oral albaconazole in patients with distal subungual onychomycosis.
    Sigurgeirsson B; van Rossem K; Malahias S; Raterink K
    J Am Acad Dermatol; 2013 Sep; 69(3):416-25. PubMed ID: 23706639
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Topical treatment of onychomycosis with efinaconazole solution 10%.
    Rich P
    Cutis; 2013 Jun; 91(6):305-7. PubMed ID: 23837154
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efinaconazole Topical Solution, 10%, for the Treatment of Mild and Moderate Toenail Onychomycosis.
    Rodriguez DA
    J Clin Aesthet Dermatol; 2015 Jun; 8(6):24-9. PubMed ID: 26155324
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Access of efinaconazole topical solution, 10%, to the infection site by spreading through the subungual space.
    Elewski BE; Pollak RA; Pillai R; Olin JT
    J Drugs Dermatol; 2014 Nov; 13(11):1394-8. PubMed ID: 25607708
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efinaconazole 10% solution in the treatment of onychomycosis of the toenails.
    Joseph WS; Vlahovic TC; Pillai R; Olin JT
    J Am Podiatr Med Assoc; 2014; 104(5):479-85. PubMed ID: 25275736
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.